Toxicity and efficacy of the cetuximab-folfox regimen in first-line of ras wild-type metastatic colorectal cancer

• Autores: Sara Gallardo Borge, Cristina Sangrador Pelluz, María Angeles López-Montenegro Soria, Susana Redondo Capafons, Julen Fernández Plana, Jordi Nicolás Picó
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 21, Nº. 3, 2019, págs. 133-139
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • A 9-year retrospective observational study (January 2009-December 2017) conducted in a 450-bed hospital. The aim of the study was to assess the toxicity and efficacy of the cetuximab-FOLFOX regimen in first-line therapy of RAS wild type metastatic colorectal cancer in daily clinical practice. The outcomes suggested a similar efficacy to prior published studies and an acceptable safety profile, mainly based on mild-moderate toxicity